Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the pace and productivity of Alnylam’s RNAi therapeutics pipeline.
More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)
12 JANUARY 2021: Paradigm4, specialist in scientific data management and scalable computation, has signed an agreement with 54gene, a health technology company deriving insights from the world’s most diverse populations to solve some of healthcare’s biggest challenges. The agreement will allow 54gene to use Paradigm4’s REVEALTM Biobank app to explore,
Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”
